Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy is a research paper published in Pharmaceuticals (2021). On theSindex it has a DataRank of 0. It has been cited 15 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA099908
U.S. Department of Defense
Grant: OC190352
American Cancer Society
Grant: ACS-IRG-15-176-41
American Cancer Society
Grant: ACS-IRG-18-165-43
National Center for Advancing Translational Sciences
Grant: UL1TR002537
National Cancer Institute
Grant: P30CA086862
National Institutes of Health
Grant: 5UL1TR002537-02
The University of Iowa Clinical and Translational Science Award
National Institutes of Health
Grant: 1P30CA086862-01
Core--Clinical trials support group
National Institutes of Health
Grant: 7R01CA099908-19
Targeted Therapy for Endometrial Cancer
FWCI
0.89
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals